Maxim Biotechnologies Overview
- Year Founded
-
1993
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$369M
Maxim Biotechnologies General Information
Description
Developer of tumor pathology immunohistochemical diagnostic reagents and testing instruments. The company's business covers tumor pathological diagnosis, immunocytochemical diagnosis, molecular pathological diagnosis, and precision medical diagnosis, enabling medical institutes to improve medical detection accuracy and reduce costs.
Contact Information
Website
www.maxim.com.cn(Operating Subsidiary)
Corporate Office
- Building 12, Haixi Innovation Park
- High-tech Zone, Wulongjiang Middle Avenue
- Fuzhou, Fujian
- China
Corporate Office
- Building 12, Haixi Innovation Park
- High-tech Zone, Wulongjiang Middle Avenue
- Fuzhou, Fujian
- China
Maxim Biotechnologies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Merger/Acquisition | 15-Jun-2020 | $369M | Completed | Generating Revenue | ||
| 1. Later Stage VC | 01-Jan-2017 | Completed | Generating Revenue |
Maxim Biotechnologies Former Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CDH Investments | PE/Buyout | Minority | ||
| GAC Capital | Corporate Venture Capital | Minority | ||
| GL Capital Group | Growth/Expansion | Minority | ||
| Taikang Insurance Group | PE-Backed Company | Minority |
Maxim Biotechnologies FAQs
-
When was Maxim Biotechnologies founded?
Maxim Biotechnologies was founded in 1993.
-
Where is Maxim Biotechnologies headquartered?
Maxim Biotechnologies is headquartered in Fuzhou, China.
-
What industry is Maxim Biotechnologies in?
Maxim Biotechnologies’s primary industry is Diagnostic Equipment.
-
Is Maxim Biotechnologies a private or public company?
Maxim Biotechnologies is a Private company.
-
What is the current valuation of Maxim Biotechnologies?
The current valuation of Maxim Biotechnologies is .
-
What is Maxim Biotechnologies’s current revenue?
The current revenue for Maxim Biotechnologies is .
-
Who are Maxim Biotechnologies’s investors?
CDH Investments, GAC Capital, GL Capital Group, and Taikang Insurance Group have invested in Maxim Biotechnologies.
-
When was Maxim Biotechnologies acquired?
Maxim Biotechnologies was acquired on 15-Jun-2020.
-
Who acquired Maxim Biotechnologies?
Maxim Biotechnologies was acquired by Beijing Strong Biotechnologies and China National Pharmaceutical Investment.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process